T
Todd E. DeFor
Researcher at University of Minnesota
Publications - 297
Citations - 19625
Todd E. DeFor is an academic researcher from University of Minnesota. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 64, co-authored 288 publications receiving 17856 citations. Previous affiliations of Todd E. DeFor include City of Hope National Medical Center.
Papers
More filters
Journal ArticleDOI
Pulmonary Risk Factors in Allogeneic Transplantation for Hurler Syndrome.
Paul J. Orchard,Satkiran S. Grewal,Carlos Milla,Elizabeth A. Braunlin,Todd E. DeFor,Angela Panoskaltsis-Mortari,William Krivit,Charles Peters +7 more
TL;DR: It is concluded that it is possible to determine standard and high risk populations of patients with Hurler syndrome based on the pre-transplant evaluation, and for patients at higher risk, alteration of the preparative regimen to reduce toxicity or prior treatment with enzyme therapy may be beneficial in achieving an improved outcome.
Journal ArticleDOI
Low Amphiregulin Expression in Intestinal Biopsies of Patients with Acute Graft-Versus-Host Disease
Khalid Amin,Yaqoob Usman,Brittney Schultz,Byron P. Vaughn,Justin Howard,Alexander Khoruts,Todd E. DeFor,Colleen L. Forster,Armin Rashidi,Daniel J. Weisdorf,Margaret L. MacMillan,Bruce R. Blazar,Angela Mortari,Shernan G. Holtan +13 more
Journal ArticleDOI
A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia
Fiona He,Smarika Sapkota,Sarah J. Parker,Todd E. DeFor,Erica D. Warlick,Celalettin Ustun,Craig E. Eckfeldt,Armin Rashidi,Andy Kurtzweil,Daniel J. Weisdorf,Nelli Bejanyan +10 more
TL;DR: Clofarabine and cytarabine (Clo’+ Ara-C- containing regimens) combinations have efficacy in treatment of acute myeloid leukemia (AML) and are an acceptable upfront therapy option for patients who are not candidates for “7 +3” induction, but do not induce durable remissions.
Journal ArticleDOI
Hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia (ALL): 25-year experience at the University of Minnesota
M. Tomblyn,Todd E. DeFor,Margaret L. MacMillan,Patrick D. Higgins,Kathryn E. Dusenbery,Daniel J. Weisdorf +5 more
TL;DR: The records of 623 consecutive patients treated with myeloablative TBI-containing conditioning and either autologous or allogeneic transplantation between 1980 and 2005 at the University of Minnesota were reviewed.
Journal ArticleDOI
Neurological Consequences of Cytokine Release Syndrome Following Subcutaneous Recombinant IL-15 and Haploidentical Donor Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia
Sarah Cooley,Fiona He,Veronika Bachanova,Greg M Vercellotti,Todd E. DeFor,Julie M. Curtsinger,Paul Alexander Robertson,Kevin C. Conlon,Thomas A. Waldmann,David H. McKenna,Bruce R. Blazar,Daniel J. Weisdorf,Jeffrey S. Miller +12 more
TL;DR: No significant correlations were found between development of CRS and absolute lymphocyte or monocyte count, presence or absence of haplo-NK expansion at day 14, number of rIL-15 doses received, or disease burden at baseline as measured by blast percentage in bone marrow.